文献速递白血病造血干细胞移植与细胞治疗

CD19 CAR-T细胞因子释放综合征的抢先干预不削弱抗白血病疗效

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.
PubMed 文献 · Blood · 2019-01-01

该研究报道了接受CD19 CAR-T(含4-1BB:zeta共刺激域、固定CD4:CD8比例)治疗的B-ALL受试者中,早期使用托珠单抗和/或糖皮质激素干预可降低轻度CRS向重度CRS的转化频率。抢先干预虽使接受托珠单抗和/或糖皮质激素的受试者数量翻倍,但未明显影响微小残留病阴性完全缓解率或功能性CAR-T细胞后续存续,也未增加神经毒性或感染后遗症风险。

要点

  • 早期托珠单抗和/或糖皮质激素干预可减少轻度CRS向重度CRS转化。
  • 抢先干预未明显损害MRD阴性完全缓解率或功能性CAR-T细胞存续。
  • 抢先干预未增加神经毒性比例或感染后遗症风险。

核心结论

  • 对出现早期CRS征象的受试者早期使用托珠单抗和/或糖皮质激素,未对CD19 CAR-T细胞的抗肿瘤效力产生负面影响。

研究设计与样本

  • 研究为一项注册于ClinicalTrials.gov(#NCT020284)的临床试验,报道了接受由固定CD4:CD8比例、含4-1BB:zeta CAR靶向CD19的CAR-T产品治疗并接受早期干预治疗的受试者中重度CRS的低发生率。

主要发现

  • 早期干预使接受托珠单抗和/或糖皮质激素的受试者数量翻倍,但与未接受干预的受试者相比,MRD阴性完全缓解率或功能性CAR-T细胞后续存续未见明显不良影响。
  • 早期干预治疗未增加经历神经毒性的受试者比例,也未使受试者面临感染后遗症风险。

临床怎么用

  • 对CD19 CAR-T治疗后出现早期CRS征象的B-ALL患者,可考虑早期使用托珠单抗和/或糖皮质激素以降低重度CRS转化风险。
  • 该抢先干预策略在不明显削弱抗白血病疗效的前提下,有助于提升复发/难治患者的治疗指数并拓宽CAR-T在ALL治疗中的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunotherapy with the adoptive transfer of T cells redirected with CD19-specific chimeric antigen receptors (CARs) for B-lineage acute lymphoblastic leukemia (ALL) can salvage >80% of patients having relapsed/refractory disease. The therapeutic index of this emerging modality is attenuated by the occurrence of immunologic toxicity syndromes that occur upon CAR T-cell engraftment. Here, we report on the low incidence of severe cytokine release syndrome (CRS) in a subject treated with a CAR T-cell product composed of a defined ratio CD4:CD8 T-cell composition with a 4-1BB:zeta CAR targeting CD19 who also recieved early intervention treatment. We report that early intervention with tocilizumab and/or corticosteroids may reduce the frequency at which subjects transition from mild CRS to severe CRS. Although early intervention doubled the numbers of subjects dosed with tocilizumab and/or corticosteroids, there was no apparent detrimental effect on minimal residual disease-negative complete remission rates or subsequent persistence of functional CAR T cells compared with subjects who did not receive intervention. Moreover, early intervention therapy did not increase the proportion of subjects who experience neurotoxicity or place subjects at risk for infectious sequelae. These data support the contention that early intervention with tocilizumab and/or corticosteroids in subjects with early signs of CRS is without negative impact on the antitumor potency of CD19 CAR T cells. This intervention serves to enhance the therapeutic index in relapsed/refractory patients and provides the rationale to apply CAR T-cell therapy more broadly in ALL therapy. This trial was registered at www.clinicaltrials.gov as #NCT020284.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Gardner RA, Ceppi F, Rivers J, et al. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood. 2019. PMID: 31697826. doi:10.1182/blood.2019001463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。